Yestar Healthcare to Review H1 2026 Results and Consider Interim Dividend on 28 August 2026

Bulletin Express

Aug 17

Yestar Healthcare Holdings Company Limited has scheduled a board meeting for 28 August 2026. Directors will review and approve the unaudited consolidated interim results for the six months ended 30 June 2026 and discuss the possible declaration of an interim dividend.

The notice, dated 17 August 2026, was signed by CEO and executive director Wang Chunlai on behalf of the Board. Current board composition includes executive directors Wang Chunlai, Qiao Jinrong and Liao Changxiang; non-executive director Hartono James; and independent non-executive directors Zeng Jinsong, Zhao Ziwei and Koeswondo Michael David.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1149917641"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149917641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149917641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149917641","market":"hk","top_or_hot":-1,"title":"Yestar Healthcare to Review H1 2026 Results and Consider Interim Dividend on 28 August 2026","media":"Bulletin Express","content":"<p>Yestar Healthcare Holdings Company Limited has scheduled a board meeting for 28 August 2026. Directors will review and approve the unaudited consolidated interim results for the six months ended 30 June 2026 and discuss the possible declaration of an interim dividend.</p>\n<p>The notice, dated 17 August 2026, was signed by CEO and executive director Wang Chunlai on behalf of the Board. Current board composition includes executive directors Wang Chunlai, Qiao Jinrong and Liao Changxiang; non-executive director Hartono James; and independent non-executive directors Zeng Jinsong, Zhao Ziwei and Koeswondo Michael David.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yestar Healthcare to Review H1 2026 Results and Consider Interim Dividend on 28 August 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYestar Healthcare to Review H1 2026 Results and Consider Interim Dividend on 28 August 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-17 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yestar Healthcare Holdings Company Limited has scheduled a board meeting for 28 August 2026. Directors will review and approve the unaudited consolidated interim results for the six months ended 30 June 2026 and discuss the possible declaration of an interim dividend.</p>\n<p>The notice, dated 17 August 2026, was signed by CEO and executive director Wang Chunlai on behalf of the Board. Current board composition includes executive directors Wang Chunlai, Qiao Jinrong and Liao Changxiang; non-executive director Hartono James; and independent non-executive directors Zeng Jinsong, Zhao Ziwei and Koeswondo Michael David.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02393","symbol_name":"巨星医疗控股","start_time":0,"source_url":"","article_id":"1149917641","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149917641","pubTimestamp":1786956311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Yestar Healthcare Holdings Company Limited has scheduled a board meeting for 28 August 2026. Directors will review and approve the unaudited consolidated interim results for the six months ended 30...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02393":"巨星医疗控股"},"translate_title":"Yestar Healthcare 将于 2026 年 8 月 28 日审查 H1 2026 业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02393":1},"content_text":"Yestar Healthcare Holdings Company Limited has scheduled a board meeting for 28 August 2026. Directors will review and approve the unaudited consolidated interim results for the six months ended 30 June 2026 and discuss the possible declaration of an interim dividend.\nThe notice, dated 17 August 2026, was signed by CEO and executive director Wang Chunlai on behalf of the Board. Current board composition includes executive directors Wang Chunlai, Qiao Jinrong and Liao Changxiang; non-executive director Hartono James; and independent non-executive directors Zeng Jinsong, Zhao Ziwei and Koeswondo Michael David.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}